The following is a press release. Their statements are their own.
Bangkok – 29 July 2021 – Zuellig Pharma, a leading healthcare services company in Asia, is working with Chulalongkorn University to develop ChulaCov19, Southeast Asia’s first COVID-19 mRNA vaccine. As part of the ChulaCov19 mRNA vaccine program, Zuellig Pharma managed the clinical trials, which included storing and distributing the vaccines to clinical sites.
On 14 June 2021, Chulalongkorn University launched the first phase of its clinical trials with 36 participants, who were subject to strict screening processes and deemed to be in good health. The trial’s first phase was aimed at assessing the vaccine’s safety, along with identifying proper doses to advance to the second phase of the trial. The trial’s second phase is expected to commence in August 2021.
“We are very grateful to Zuellig Pharma Thailand who has provided us with world-class clinical trial management as well as storage and distribution support for the ChulaCov19 mRNA vaccine program. We hope that our home-grown mRNA vaccine can be manufactured and supplied as part of the national vaccine roll-out program next year if proven to be safe and efficacious,” said Professor Dr. Suttipong Wacharasindhu, Director of Chulalongkorn Hospital and Dean of Chula Faculty of Medicine
Professor Dr. Kiat Ruxrungtham, M.D., Director of the ChulaCov19 mRNA vaccine development program, added that Zuellig Pharma supported the development of the Chula-Cov 19 vaccine with strict clinical trial procedures and handling to sustain temperatures as low as -70° from deliveries into warehouses, through to the last mile of transportation to clinical sites.
“We are proud and honored to be part of the ChulaCov19 project, providing services that will benefit the citizens of Thailand and make healthcare more accessible. We offer the largest cold chain warehouse and delivery operation in Thailand, along with best-in-class solutions and packaging materials to ensure that vaccines can be stored according to their unique requirements,” said Pucknalin Bulakul, Chief Executive of Zuellig Pharma Thailand.
For more information, please contact:
ABOUT Zuellig Pharma
Zuellig Pharma is one of the largest healthcare services groups in Asia and our purpose is to make healthcare more accessible. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started almost a hundred years ago and has grown to become a US$13 billion business covering 13 markets with over 12,000 employees. Our people serve over 350,000 medical facilities and work with over 1,000 clients, including the top 20 pharmaceutical companies in the world.
More recently, we launched our Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia. Since then, our teams have been focused on creating data, digital, and disease management solutions, supporting patients with chronic conditions, and helping payors manage healthcare costs.